A venture capital fund founded in 2015 and based in China closed its second fund at ¥100M that again focuses on opportunities in China. The firm invests in early-stage life science ventures from Seed to Series A. Typical initial size of investment ranges from $500k-1M USD.
The firm will consider medical devices especially minimally invasive medical devices, and diagnostics. Within medical devices, the fund is interested in 510k and software-enabled devices and looks at the in-development phase (must include proof of concept). Particularly, the firm is interested in devices related to digital technology such as artificial intelligence. Within diagnostics, the firm is interested in in-vitro diagnostics that are in-development. The main indication areas of interest are heart disease, infectious disease, chronic disease, and rehabilitation.
The firm prefers to work with a management team with established industry partners. The fund also prefers the CEO to have expertise in the respective life science fields. The fund is open to both leading and co-investing and will not require board seating. Although it has a China focus, the fund has supporting partners who are able to work with offshore companies that are interested in attaining proof of concept in China.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment